Ryusuke Murakami

17PUBLICATIONS
59CO-AUTHORS
Tumour immunologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Pacific Peoples sport and physical activityMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 10, 2026
AI-Based Analysis of Tumor-Infiltrating Lymphocytes and Homologous Recombination in Ovarian Cancer: JGOG3025-A1 Study.

|May 22, 2026
Distinct clinical and prognostic features of cervical adenosquamous carcinoma: a nationwide registry-based and propensity score-matched analysis.

|Mar 12, 2026
A Novel CDK12 Inhibitor Induces Homologous Recombination Deficiency to Enhance PARP Inhibitor Efficacy in Uterine Serous Carcinoma.

Shunsuke Kawahara, Mana Taki, Junzo Hamanishi

|Jan 27, 2026
Oligoclonal B cell expansion and passenger fusion genes predict response to Nivolumab in recurrent ovarian cancer: phase II Kyoto trial.

Ryusuke Murakami, Junzo Hamanishi, J B Brown

|Jul 08, 2025
Low-dose oral cyclophosphamide with or without bevacizumab treatment in patients with recurrent ovarian and cervical cancer before best supportive care.

Yusuke Kawaguchi, Ryusuke Murakami, Akihiro Yanai

|Dec 27, 2024
Changes in Physical Activity Across Cancer Diagnosis and Treatment Based on Smartphone Step Count Data Linked to a Japanese Claims Database: Retrospective Cohort Study.

Yoshihide Inayama, Ken Yamaguchi, Kayoko Mizuno

Pageof 3

Frequent Collaborators

9 joint publications

Junzo Hamanishi

7 joint publications

Masaki Mandai

6 joint publications

Koji Yamanoi

5 joint publications

Mana Taki